Human tumor models in the severe combined immune deficient (scid) mouse.

摘要: Purpose: To test a number of established human tumor cell lines and early passage breast cancer (UACC2150) melanoma cells (UACC1273) for growth in the scid mouse tumors' response to conventional chemotherapeutic drugs. Methods: Established (A375, C81-61), colon (SW480), lung (A549), lymphomoblastoid leukemia (LCL-B), promyelocytic (HL60), prostate (PC-3, DU145), (MCF7) were injected at subcutaneous (s.c.), intraperitoneal (i.p.), or mammary fat pad (MFP) sites. Tumor volume curves survival various lines. Carmustine (BCNU), cisplatin (CDDP), cyclophosphamide (CPA), doxorubicin, dacarbazine (DTIC), tamoxifen vincristine s.c. i.p.. The drug effects on volumes determined. Results: occurred with each type. After i.p. injection, 90% mortality within 26 60 days except line UACC1273 which approximately 90 days. In MCF7 model, treatment (P < 0.001) CPA 0.0001) resulted significant delay compared control groups. BCNU CDDP delays relative SW480 0.0014) A375 models, respectively. doxorubicin improved HL60 model = 0.0018). Conclusions: These models appear reflect clinical situation that clinically active drugs are similarly models. Therefore, may be useful testing new agents against types.